Biotech Stocks Reviews
- XBI Drawdowns & Management Execution
Wed, Oct 20
The biotech route has been long and painful. Actually, the longest drawdown in XBI since its inception, · more » - Novavax Lack of Execution Overshadows Great Vaccine Data
Tue, Oct 19
Novavax continues to face regulatory hurdles with their COVID vaccine, and it has been reflected in the · more » - Names To Watch With XBI Hit
Mon, Oct 11
Biotech (XBI) is back under $125 after a small September rally. On biotech weakness, we’re looking to · more » - Affimed’s AFM24 Monotherapy Has Yet To Show Clinical Responses
Wed, Sep 8
Affimed (AFMD)releasedQ2 2021 business update today and it was mixed. AFM13 + MD Anderson collaboration · more » - This Name Is Overlooked While Rest of IL-2 Space Is In A Frenzy
Tue, Sep 7
Medicenna (MDNA) is developing a next-gen IL-2 candidate against solid tumors. The company expects to · more » - Regulatory Bodies In No Rush To Get Novavax Vaccine Approved
Tue, Aug 31
The FDA granted Pfizer and partner BioNTech full approval for their vaccine last week. Meanwhile, there · more » - Trillium’s (TRIL) Takeout Further Validates Macrophages in Cancer Fight
Mon, Aug 23
Biotech got a jolt of life after Pfizer announced the $2.26B acquisition of Trillium (TRIL), at a 204% · more » - Fate Presents Good, Not Great Durability for NK Cells
Fri, Aug 20
Fate Therapeutics (FATE)reportedadditional data for their two off-the-shelf NK cell programs after · more » - Eloxx Setting Expectations for Phase 2 CF Data
Wed, Aug 18
Eloxx (ELOX)provideda Q2 business update earlier this week, and everything was on schedule. Based on · more »